Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Core Viewpoint - Kymera Therapeutics, Inc. has successfully closed an upsized underwritten public offering, raising $602.0 million through the sale of 8,050,000 shares of common stock at a price of $86.00 per share, resulting in gross proceeds of approximately $692.3 million before expenses [1][2]. Company Overview - Kymera Therapeutics is a clinical-stage biotechnology company focused on developing targeted protein degradation (TPD) therapies for immunological diseases, aiming to create a new generation of oral small molecule degrader medicines [6]. - The company has advanced its first degrader into clinical trials and is committed to building a robust pipeline of innovative therapies that address critical health issues [6]. - Founded in 2016, Kymera has been recognized as one of Boston's top workplaces in recent years [6]. Offering Details - The public offering was managed by a consortium of financial institutions including Morgan Stanley, J.P. Morgan, Jefferies, Stifel, Guggenheim Securities, and Wells Fargo Securities [2]. - The offering was conducted under an automatically effective shelf registration statement filed with the SEC on October 31, 2024 [3]. - A final prospectus supplement detailing the terms of the offering has been filed with the SEC and is available for public access [4].